Tag Archives: AMD

November, 2018

October, 2018

August, 2018

July, 2018

August, 2017

June, 2017

February, 2017

December, 2016

  • 12 December

    Ophthotech’s Anti-PDGF Therapy Fails Phase 3 Trials for Treatment of Wet AMD

    NEW YORK–(BUSINESS WIRE)– Ophthotech Corporation (Nasdaq:OPHT) today announced that the pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its two pivotal Phase 3 clinical trials investigating the superiority of Fovista® (pegpleranib) anti-PDGF therapy in combination with Lucentis® (ranibizumab) anti-VEGF therapy compared to Lucentis® monotherapy …

October, 2016

  • 17 October

    FDA Approves Genentech’s Lucentis Prefilled Syringe

    SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved the Lucentis® (ranibizumab injection) 0.5 mg prefilled syringe (PFS) as a new method of administering the medicine. Like the Lucentis 0.5 mg vial, …

  • 13 October

    Ocular Therapeutix and Regeneron Collaborate for Development of New Eylea Formulation

    BEDFORD, Mass–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has entered into a strategic collaboration, option and license agreement with Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Ocular and Regeneron will …